

# The *TgsGP* Gene Is Essential for Resistance to Human Serum in *Trypanosoma brucei gambiense*

Paul Capewell<sup>1</sup>\*, Caroline Clucas<sup>1</sup>\*, Eric DeJesus<sup>2</sup>, Rudo Kieft<sup>2</sup>, Stephen Hajduk<sup>2</sup>, Nicola Veitch<sup>1</sup>, Pieter C. Steketee<sup>1</sup>, Anneli Cooper<sup>1</sup>, William Weir<sup>1</sup>, Annette MacLeod<sup>1\*</sup>

**1** Wellcome Centre for Molecular Parasitology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, **2** Department of Biochemistry and Molecular Biology, University of Georgia, Athens, Georgia, United States of America

## Abstract

*Trypanosoma brucei gambiense* causes 97% of all cases of African sleeping sickness, a fatal disease of sub-Saharan Africa. Most species of trypanosome, such as *T. b. brucei*, are unable to infect humans due to the trypanolytic serum protein apolipoprotein-L1 (APOL1) delivered via two trypanosome lytic factors (TLF-1 and TLF-2). Understanding how *T. b. gambiense* overcomes these factors and infects humans is of major importance in the fight against this disease. Previous work indicated that a failure to take up TLF-1 in *T. b. gambiense* contributes to resistance to TLF-1, although another mechanism is required to overcome TLF-2. Here, we have examined a *T. b. gambiense* specific gene, *TgsGP*, which had previously been suggested, but not shown, to be involved in serum resistance. We show that *TgsGP* is essential for resistance to lysis as deletion of *TgsGP* in *T. b. gambiense* renders the parasites sensitive to human serum and recombinant APOL1. Deletion of *TgsGP* in *T. b. gambiense* modified to uptake TLF-1 showed sensitivity to TLF-1, APOL1 and human serum. Reintroducing *TgsGP* into knockout parasite lines restored resistance. We conclude that *TgsGP* is essential for human serum resistance in *T. b. gambiense*.

**Citation:** Capewell P, Clucas C, DeJesus E, Kieft R, Hajduk S, et al. (2013) The *TgsGP* Gene Is Essential for Resistance to Human Serum in *Trypanosoma brucei gambiense*. PLoS Pathog 9(10): e1003686. doi:10.1371/journal.ppat.1003686

**Editor:** Sam Alford, London School of Hygiene and Tropical Medicine, United Kingdom

**Received:** June 10, 2013; **Accepted:** August 22, 2013; **Published:** October 3, 2013

**Copyright:** © 2013 Capewell et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** PC, CC, NV, AC, WW, AM are funded by a Wellcome Senior Fellowship Grant awarded to AM. PCS is a Wellcome funded research student. The Wellcome Trust Centre for Molecular Parasitology is supported by core funding from the Wellcome Trust [085349]. RK, ED and SH are supported by NIH grant AI039033. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

\* E-mail: annette.macleod@glasgow.ac.uk

† These authors contributed equally to this work.

## Introduction

Throughout their evolution in sub-Saharan Africa, humans have been under assault by a range of different pathogens. One defining challenge is that posed by African trypanosomes, a species complex of blood-borne protozoan parasites transmitted by tsetse flies [1]. The principle pathogenic species in Africa are *Trypanosoma brucei*, *T. congolense* and *T. vivax*, although only *Trypanosoma brucei* sub-species are able to infect humans. A key feature of these parasites is the ability to undergo antigenic variation by modifying the variant specific glycoprotein (VSG) enveloping the cell that renders the mammalian adaptive immune system largely ineffective [2]. Components of the innate immune system therefore contribute significantly to defence against these organisms [3]. Critical to these defences is the serum protein apolipoprotein L1 (APOL1) found in some catarrhine primates, including humans [4,5]. The protein is able to kill the majority of trypanosome species in a dose-dependent manner [5]. APOL1 is delivered to parasites in two fractions of the high-density lipoprotein (HDL) component of serum, termed trypanolytic factor 1 and 2 (TLF-1 and TLF-2) [6]. TLF-1 binds to the parasite through an interaction between the haptoglobin-related protein (HPR) surrounding the TLF-1 particle and the haptoglobin haemoglobin receptor (HpHbR) in the flagellar pocket of the parasite [7–9]. Under the acidic conditions found in the lysosome, APOL1

changes conformation and embeds in the lysosomal membrane, forming pores in the organelle, leading to cell death [5,10]. A proportion of TLF-2 similarly enters trypanosomes via HpHbR, although an alternate route also contributes to uptake [11].

Although TLF-1 and 2 kill the majority of trypanosome species, two sub-species of *T. brucei* have evolved to overcome this innate immunity. *T. b. rhodesiense* and *T. b. gambiense* are both resistant to lysis by APOL1 and establish bloodstream infections in humans [1]. *T. b. rhodesiense* causes an acute form of the disease and is found in East Africa whereas *T. b. gambiense* is found in West and Central Africa. *T. b. gambiense* causes a more chronic form of the disease and is responsible for 97% of all human cases of trypanosomiasis [12]. The mechanism of human serum resistance for *T. b. rhodesiense* involves the expression of a truncated VSG, termed serum resistance associated (SRA) protein [13,14]. SRA binds to APOL1 in the lysosome, preventing lysis [14]. However, the *SRA* gene is absent from *T. b. gambiense*, the more prevalent human infective sub-species [15]. The *T. b. gambiense* subspecies consists of two sub-groups (1 and 2) that differ in phenotype, including their associated pathology. Group 1 *T. b. gambiense* parasites are the most prevalent of the human infective trypanosomes and are responsible for the vast majority of cases [16]. Group 1 *T. b. gambiense* can be distinguished by both their reduced efficacy of HpHbR for binding TLF-1, due to a conserved single nucleotide polymorphism [17–19] and also by the presence of a specific truncated *VSG*, *TgsGP*

## Author Summary

*Trypanosoma brucei gambiense* causes 97% of all cases of African sleeping sickness, a fatal disease of sub-Saharan Africa. Most species of trypanosome, such as *T. b. brucei*, are unable to infect humans due to trypanolytic factors in human serum. Understanding how *T. b. gambiense* overcomes these factors and infects humans is of major importance in the fight against this disease. Previous work indicated that a failure to take up some trypanolytic factors by *T. b. gambiense* contributes to resistance, although other mechanisms are involved. Here, we have examined a *T. b. gambiense* specific gene, *TgsGP*, for involvement in resistance to human serum. We show that *TgsGP* is essential for resistance to lysis as deletion of *TgsGP* in *T. b. gambiense* renders the parasites sensitive to most trypanolytic factors. *TgsGP* deletion in *T. b. gambiense* modified to overcome the sub-species trait to reduce uptake of some trypanolytic factors resulted in sensitivity to all trypanolytic factors. Reintroducing *TgsGP* into these knockout parasite lines restored resistance. We conclude that *TgsGP* is essential for human serum resistance in *T. b. gambiense*.

[20]. The *TgsGP* gene is present in all group 1 isolates examined to date but not in *T. b. brucei*, *T. b. rhodesiense* or group 2 *T. b. gambiense* [20–23]. The specificity of *TgsGP* to group 1 *T. b. gambiense* and its resemblance to *SRA*, in that it is a truncated *VSG* gene, led to a suggestion that this gene may confer human serum resistance to group 1 *T. b. gambiense* [20]. The gene was transfected into *T. b. brucei* where it did not confer increased resistance to human serum. It was hypothesized that if *TgsGP* was involved in human serum resistance other factors would also be required to confer the phenotype in *T. b. brucei* [20]. Efforts to delete the gene from *T. b. gambiense* were unsuccessful and the function of *TgsGP* remained unknown [20]. Here we have successfully deleted the *TgsGP* gene from *T. b. gambiense* and demonstrated that it is essential for human serum resistance and requires a *T. b. gambiense* genetic background in order to function.

## Results

### Deletion of *TgsGP* in wild-type group 1 *T. b. gambiense*

To assess whether *TgsGP* is involved in human serum resistance in *T. b. gambiense*, the gene was deleted from the genome of a group 1 *T. b. gambiense* strain. All strains of *T. b. gambiense* investigated so far are hemizygous for *TgsGP*, allowing a complete knockout with just one round of transfection [20–22]. Although it was postulated that *TgsGP* was an essential gene and could not be deleted [20], several *TgsGP*<sup>-/-</sup> clones were generated in this study. One of the clones was selected for analysis and used for subsequent assays. The deletion of *TgsGP* from the clone was confirmed by PCR (Figure 1A). The *TgsGP*<sup>-/-</sup> *T. b. gambiense* clones was unable to survive in the presence of normal human serum (Figure 2) or recombinant APOL1 (Figure 2), with significantly fewer surviving cells compared to wild-type *T. b. gambiense* (human serum t-test  $p = 0.001$ , APOL1 t-test  $p < 0.001$ ). The clone grew in the presence of non-lytic serum in a similar manner to wild-type *T. b. gambiense* (t-test  $p = 0.145$ ). This indicates that *TgsGP* is involved in protecting against the trypanolytic protein APOL1.

The clone was able to grow in the presence of TLF-1 and the number of cells after 24 hours does not differ significantly from that of the wild-type *T. b. gambiense* strain (t-test  $p = 0.511$ ). Wild-type *T. b. gambiense* is resistant to lysis by TLF-1 due to reduced

efficacy of their HpHbR for binding TLF-1. Thus lethal amounts of the lytic particle are not internalised by the parasites [18,19]. It is likely that *TgsGP*<sup>-/-</sup> *T. b. gambiense* clones are able to grow in the presence of TLF-1 because it possesses the *T. b. gambiense* HpHbR allele that is less efficient at binding TLF-1.


### Deletion and reintroduction of *TgsGP* in *TbbHpHbR*<sup>-/+</sup> *T. b. gambiense*

As previously detailed, group 1 *T. b. gambiense* is characterised by a non-functional HpHbR which results in a reduced uptake of TLF-1 and to a lesser extent TLF-2 [17–19,24]. To investigate the effect of the loss of *TgsGP* in combination with TLF-1 uptake, a *T. b. gambiense* strain expressing a functional *T. b. brucei* HpHbR (*TbbHpHbR*) and lacking *TgsGP* was created (termed *TbbHpHbR*<sup>-/+</sup> *TgsGP*<sup>-/-</sup>). Expression of both wild-type and ectopic *TbbHpHbR* alleles was confirmed by RT-PCR (Figure 1B). An allele-specific *HpyCh4V* restriction site present in the open reading frame of *TbbHpHbR*, but absent in *TbgHpHbR*, was used to distinguish between the alleles (Figure 1B) and demonstrated that both alleles were expressed, although the *TbgHpHbR* allele exhibits lower expression relative to the *TbbHpHbR* allele. The strain expresses a fully functional HpHbR and hence takes up TLF-1 to a degree similar to *T. b. brucei*, confirmed by fluorescence microscopy (Figure 3). *TbbHpHbR*<sup>-/+</sup> *TgsGP*<sup>-/-</sup> *T. b. gambiense* clones were killed in the presence of normal human serum, recombinant APOL1 or, unlike *TgsGP*<sup>-/-</sup> clones, physiological levels of TLF-1 (Figure 2). The number of remaining cells at 24 hours was significantly lower than wild-type *T. b. gambiense* (human serum t-test  $p = 0.001$ , TLF-1 t-test  $p < 0.001$ , APOL1 t-test  $p < 0.001$ ). However, the cells were able to grow in the presence of non-lytic serum in a similar manner to wild-type *T. b. gambiense* (t-test = 0.690). A *T. b. gambiense* clone with *TgsGP* and the functional *TbbHpHbR* was able to grow in the presence of human serum and APOL1 (Figure 2) with cell number not significantly differing from wild-type *T. b. gambiense* (human serum t-test  $p = 0.936$ , APOL1 t-test  $p = 0.465$ ) or in the presence of non-lytic serum (t-test  $p = 0.972$ ). However, the clone displayed a trypanostatic growth effect in physiological levels of purified TLF-1 with significantly fewer surviving cells compared to wild type (Figure 2) (t-test  $p = 0.001$ ).

To confirm that the loss of resistance to human serum, APOL1 and TLF-1 in *TbbHpHbR*<sup>-/+</sup> *TgsGP*<sup>-/-</sup> *T. b. gambiense* was due to the loss of *TgsGP*, the gene was re-introduced into this background. Resistance to human serum, TLF-1 and APOL1 was rescued by the re-introduction of *TgsGP*, confirming that this gene is essential for resistance to lysis (Figure 2). When the same *TgsGP* add-back construct was transfected into a human serum sensitive *T. b. brucei*, it did not confer resistance to any lytic component (Figure 2), confirming earlier work [20].

### Localisation of *TgsGP*

Previous work has shown that *TgsGP* localises to the flagellar pocket in *T. b. gambiense* and this is likely to be the site of interaction between TLF and *TgsGP* [20]. A possible hypothesis for the observation that when *TgsGP* is transfected into in *TbbHpHbR*<sup>-/+</sup> *TgsGP*<sup>-/-</sup> *T. b. gambiense* background it restores human serum resistance but does not confer resistance in *T. b. brucei* [20] (figure 2) is that the protein is not trafficked correctly to the flagellar pocket. In order to verify localisation, *TgsGP* was transfected into wild-type *T. b. brucei* with the addition of a TY tag into a *HindIII* restriction site at position 1130 of the *TgsGP* ORF, upstream of the predicted GPI anchor sequence [25,26]. Immunofluorescence with anti-TY antibodies shows clear localisation of TY-*TgsGP* adjacent to the kinetoplast and co-localization with fluorescent Concanavalin A,




**Figure 1. PCR amplification of *TgsGP* and RT-PCR of *HpHbR* in wild-type and transfected lines.** (A) Amplification of *TgsGP* and a control gene (cathepsin L) by PCR in [1] wild-type *T. b. brucei* [2], *TgsGP*<sup>-/+</sup> *T. b. brucei* [3], wild-type *T. b. gambiense*, [4] *TgsGP*<sup>-/-</sup> *T. b. gambiense* [5] and negative control. (B) RT-PCR amplification of *HpHbR* followed by *HpyCH4V* restriction digestion of [1] wild-type *T. b. brucei*, [2] wild-type *T. b. gambiense* and [3] *TbbHbHpR*<sup>-/+</sup> *TgsGP*<sup>-/-</sup> *T. b. gambiense*. doi:10.1371/journal.ppat.1003686.g001

which acts as a marker for the flagellar pocket [27], (Figure 4). However, these cells were killed in human serum, TLF-1 or APOL1 (Figure S1). A similar localisation is observed when the TY-tagged *TgsGP* protein is expressed in *TbbHbHpR*<sup>-/+</sup> *TgsGP*<sup>-/-</sup> *T. b. gambiense* (Figure 4), with strong signal close to the kinetoplast and a more diffuse signal closer to the nucleus. In this case, the capacity to grow in human serum, TLF-1 and APOL1 was restored by the reintroduction of the TY-tagged *TgsGP* (Figure S1). As an identical construct was used in both transfections, it is probable that group 1 *T. b. gambiense* possess a protein or mechanism complementing *TgsGP* that is absent in *T. b. brucei*.


## Discussion

This study demonstrates that the *TgsGP* gene is essential for resistance to human serum in the most clinically important *T. b. brucei* sub-species, group 1 *T. b. gambiense*. Previous work has shown

that *TgsGP* did not confer resistance to human serum when ectopically expressed in *T. b. brucei* [20], which was confirmed here. As originally hypothesized [20], it appears likely that this is due to other factor(s) or mechanism(s) that works in concert with *TgsGP*, which are absent in *T. b. brucei*. By removing *TgsGP* from *T. b. gambiense* itself, we have demonstrated that the gene is necessary for resistance to human serum. Elucidation of a gene essential to human serum resistance in group 1 *T. b. gambiense* unlocks new avenues for future treatment of human African sleeping sickness. These include peptide screens that neutralise the *TgsGP* protein, targeted antibodies or the possibility of using *TgsGP* as a vaccine candidate, as expression is required for parasite survival in humans. Additionally, there exists the potential that variants of APOL1 may offer protection against *T. b. gambiense*. Sera from individuals possessing certain APOL1 alleles has been shown to affect the growth of *T. b. rhodesiense* and it has been suggested that these alleles may be protective against *T. b.*



**Figure 2. *TgsGP* is essential for resistance to human serum in *T. b. gambiense*.** The number of surviving cells after 24 hours incubation with 20% human serum (open box), 10 µg/ml TLF-1 (dark grey box), 50 µg/ml recombinant APOL1 (light grey box) or a non-lytic 20% FBS control (black box). The dotted line indicates the starting concentration of  $5 \times 10^5$  cells. The cell lines assayed were wild-type *T. b. brucei*; *TgsGP*<sup>-/+</sup> *T. b. brucei*; wild-type *T. b. gambiense*; *TgsGP*<sup>-/-</sup> *T. b. gambiense*; *TbbHbHpR*<sup>-/+</sup> *T. b. gambiense*; *TbbHbHpR*<sup>-/+</sup> *TgsGP*<sup>-/-</sup> *T. b. gambiense* and *TbbHbHpR*<sup>-/+</sup> *TgsGP*<sup>-/+</sup> *T. b. gambiense*. Standard error is shown, n = 4 for each data point. doi:10.1371/journal.ppat.1003686.g002



**Figure 3. Uptake of TLF-1 across strains.** Uptake of TLF-1 after one hour in [1] wild-type *T. b. brucei* [2] wild-type *T. b. gambiense* and [3] *TbbHbHpR*<sup>-/-</sup> *TgsGP*<sup>-/-</sup> *T. b. gambiense* by co-localization of fluorescently tagged TLF-1 (green) with the lysosomal marker Lysotracker (red). The kinetoplast and nucleus were also stained using DAPI (blue).  
doi:10.1371/journal.ppat.1003686.g003

*rhodesiense* [28,29]. However, this has yet to be confirmed in a case control study. Nevertheless, it is likely that there are variant APOL1 alleles that protect against group 1 *T. b. gambiense* in resistant individuals, such as the reportedly resistant Bambuti people of the Mbomo region in the Democratic Republic of the Congo [30] or recently described asymptomatic and self-cured cases from Côte d'Ivoire [31].


One other benefit of our study is the trypanosome research community now possesses a representative group 1 *T. b. gambiense* strain that is easily cultured, is no longer human serum resistant, yet only differs from the wild-type by a single gene. This is a powerful biological resource that could replace *T. b. brucei* as the

common laboratory model for the human disease, which maybe useful, particularly as several drugs display different efficacies between sub-species [1]. As such, identifying *TgsGP* as a gene essential for resistance to human serum in group 1 *T. b. gambiense* will likely be important to future control of the disease.

## Materials and Methods

### Trypanosomes strains and maintenance

Bloodstream form *T. b. brucei* Lister 427 (MITat 1.2) was grown at 37°C under 5% CO<sub>2</sub> in HMI9 medium supplemented with 20% foetal bovine serum (Sigma-Aldrich) and 20% Serum-Plus



**Figure 4. Localisation of TY-TgsGP.** Localisation of TY-tagged TgsGP (red) relative to un-endocytosed FITC-labeled Concanavalin A bound to glycoproteins in the flagellar pocket (green) and DAPI stained nucleus and kinetoplast (blue) in [1] *TY-TgsGP*<sup>-/-</sup> *T. b. brucei* and [2] *TbbHbHpR*<sup>-/-</sup> *TY-TgsGP*<sup>-/-</sup> *T. b. gambiense*. The flagellar pocket (revealed by Concanavalin A and kinetoplast position) is indicated with a white arrow.  
doi:10.1371/journal.ppat.1003686.g004

(Sigma-Aldrich). The bloodstream form group 1 *T. b. gambiense* strain ELIANE (MHOM/CI/52/ELIANE) was isolated from a patient infected while in Côte d'Ivoire [22]. It was cultured in modified HMI9 [32] supplemented with 20% serum plus (SAFC Biosciences Ltd.). Similar to other group 1 *T. b. gambiense* strains, ELIANE is consistently resistant to lysis by human serum, despite repeated passage.

### Transfection of *T. b. brucei* and group 1 *T. b. gambiense*

*T. b. gambiense* and *T. brucei* strains were transfected using the protocols outlined in [33]. For ectopic expression of *TgsGP* in *T. b. brucei* and reinsertion into the *TgsGP*<sup>-/-</sup> *T. b. gambiense* strains, the *TgsGP* ORF was inserted into the pURAN vector [34] using G418 for selection. Ectopic expression of *TbbHbHpR* in *T. b. gambiense* was achieved using the tubulin-targeting *TbbHbHpR* pTub-phelo construct, using phleomycin for selection [17]. For deletion of *TgsGP* from the genome of *T. b. gambiense* and *TbbHbHpR*<sup>-/+</sup> *T. b. gambiense*, 500 base pairs from both the upstream and downstream regions of *TgsGP* (sequence AM237444.1, <http://www.genedb.org>) were inserted into a vector containing a hygromycin resistance cassette. Insertion of TY-tagged *TgsGP* into the deletion strain *T. b. gambiense* and *T. b. brucei* was performed by inserting a TY tag into a *HindIII* restriction site at position 1130 of the *TgsGP* ORF. This sequence was ligated into the pURAN vector [34,35] and transfectants were screened using a G418 selection marker. This insertion site is upstream of the predicted GPI anchor site identified using the big-PI software package [25] and a GPI prediction protocol validated for trypanosomes [26]. Correct integration for constructs was assessed by PCR and/or RT-PCR. All primers used in the studies and their targets, are listed in Table S1.

### RT-PCR of expressed *TbbHbHpR* in group 1 *T. b. gambiense*

Total RNA was isolated from cells using RNeasy kit (Qiagen) according to manufacturers' instruction, with additional DNase steps. 2 µg RNA was subject to a second round of DNase treatment (Invitrogen) prior to cDNA synthesis using Superscript III (Invitrogen), according to manufacturers' instructions. RT-PCR was performed using *Taq* DNA polymerase and the primers are described in Table S1. For RFLP analysis of *HpHpR*, the amplified product was cleaned using GeneJet PCR purification column, digested with *HpaI* and the digested products separated on a 2% agarose gel.

### TLF-1 purification

TLF-1 purification, labeling and survival assays were performed as previously described [17,36].

### Generation of recombinant APOL1

APOL1 synthesis and purification was performed as previously described [36]. Protein purity was estimated using a Nanodrop spectrometer (Nanodrop) and SDS-PAGE. A Western blot using an antibody raised against an APOL1 peptide (Sigma-Aldrich) was used to verify that the bands present were APOL1.

### Lysis survival assays

To assess survival in human serum, trypanosomes were diluted to 5 × 10<sup>5</sup> per ml in HMI9 and incubated for 24 hours with 20%

human serum or 20% non-lytic foetal bovine serum (FBS). The number of surviving trypanosomes in each well was recorded after 24 hours using a haemocytometer. To assess survival in TLF-1 and APOL1, trypanosomes were diluted to 5 × 10<sup>5</sup> per ml in HMI9 with FBS. Cells were incubated with a physiological amount of TLF-1 (10 µg/ml). For the recombinant APOL1 assays, a concentration of 50 µg<sup>-1</sup> ml was used as this had previously been determined to kill 100% of *T. b. brucei* cells in a 24-hour assay [36]. The number of cells in each well was counted with a haemocytometer at 24 hours. There were four replicates for each data point. The number of surviving cells for each treatment were compared between each of the *T. b. gambiense* clones and wild-type *T. b. gambiense* using the unpaired 2-tailed t-test function of the Minitab 14 Statistics Package (Minitab).

### Immunofluorescence assays

TLF-1 immunofluorescence assays were performed as previously described [17,36]. Immunofluorescence localisation of TY-TgsGP was performed with approximately 10<sup>6</sup> bloodstream-cultured parasites in mid-log phase. Cells were incubated with 5 mg/ml FITC conjugated Concanavalin A in serum-free HMI9 for 20 minutes at 4°C. The Concanavalin A binds to glycoproteins in the flagellar pocket but is not endocytosed due to the reduced temperature, thus labeling the flagellar pocket [27]. Cells were then fixed by immersion in chilled methanol for 30 minutes. Slides were incubated for 1 hour with 1:500 primary mouse anti-TY antibody (Iain Johnston, University of Glasgow), washed with PBS and then incubated with 1:1000 of AlexaFluor568 anti-mouse secondary (Invitrogen). The slides were mounted using 50% glycerol, 0.1% DAPI and 2.5% DABCO. Parasites were imaged using a Deltavision Core system and SoftWorx package (Applied Precision). Images were composited using the ImageJ software package [37].

### Supporting Information

**Figure S1 TY-TgsGP behaves similarly to TgsGP.** The number of surviving cells after 24 hours incubation with 20% human serum (open box), 10 µg/ml TLF-1 (dark grey box), 50 µg/ml recombinant APOL1 (light grey box) or a non-lytic 20% FBS control (black box). The dotted line indicates the starting concentration of 5 × 10<sup>5</sup> cells. The cell lines assayed were TY-*TgsGP*<sup>-/+</sup> *T. b. brucei* and *TbbHbHpR*<sup>-/+</sup> TY-*TgsGP*<sup>-/-</sup> *T. b. gambiense*. Standard error is shown, n = 2 for each data point. (DOCX)

**Table S1 Primers used and their function.** (DOCX)

### Acknowledgments

We would like to thank Prof. Eileen Devaney, Prof. Dan Haydon and Prof. Andy Tait for their aid in preparing this manuscript and to Iain Johnston for the mouse anti-TY antibody.

### Author Contributions

Conceived and designed the experiments: PC CC AM SH AM. Performed the experiments: PC CC NV PCS ED RK AC. Analyzed the data: PC WW AM. Contributed reagents/materials/analysis tools: PC AC RK SH. Wrote the paper: PC CC WW SH AML.

### References

- Barrett MP, Burchmore RJS, Stich A, Lazzari JO, Frasch AC, et al. (2003) The trypanosomiasis. *Lancet* 362: 1469–1480. doi:10.1016/S0140-6736(03)14694-6.
- Vincendeau P, Bouteille B (2006) Immunology and immunopathology of African trypanosomiasis. *An Acad Bras Cienc* 78: 645–665.

3. Pays E, Vanhollenbecke B (2009) Human innate immunity against African trypanosomes. *Current Opinion in Immunology* 21: 493–498.
4. Poelvoorde P, Vanhamme L, Abbeele JVD, Switzer WM, Pays E (2004) Distribution of apolipoprotein L-I and trypanosome lytic activity among primate sera. *Mol Biochem Parasitol* 134: 155–157. doi:10.1016/j.molbio-para.2003.11.006.
5. Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, Nolan DP, Lins L, et al. (2003) Apolipoprotein L-I is the trypanosome lytic factor of human serum. *Nature* 422: 83–87. doi:10.1038/nature01461.
6. Raper J, Portela MPM, Lugli E, Frevert U, Tomlinson S (2001) Trypanosome lytic factors: novel mediators of human innate immunity. *Current Opinion in Microbiology* 4: 402–408.
7. Vanhollenbecke B, De Muylder G, Nielsen MJ, Pays A, Tebabi P, et al. (2008) A Haptoglobin-Hemoglobin Receptor Conveys Innate Immunity to *Trypanosoma brucei* in Humans. *Science* 320: 677–681. doi:10.1126/science.1156296.
8. Shiflett AM, Bishop JR, Pahwa A, Hajduk SL (2005) Human high density lipoproteins are platforms for the assembly of multi-component innate immune complexes. *J Biol Chem* 280: 32578–32585.
9. Shiflett A, Faulkner SD, Cotlin LF, Widener J, Stephens N, et al. (2007) African trypanosomes: intracellular trafficking of host defense molecules. *J Eukaryot Microbiol* 54: 18–21. doi:10.1111/j.1550-7408.2006.00228.x.
10. Campillo N, Carrington M (2003) The origin of the serum resistance associated (SRA) gene and a model of the structure of the SRA polypeptide from *Trypanosoma brucei rhodesiense*. *Mol Biochem Parasitol* 127: 79–84. doi:10.1016/S0166-6851(02)00306-7.
11. Bullard W, Kieft R, Capewell P, Veitch NJ, Macleod A, et al. (2012) Haptoglobin-hemoglobin receptor independent killing of African trypanosomes by human serum. *Virulence* 3: 72–76.
12. Simarro PP, Diarra A, Postigo JAR, Franco JR, Jannin JG (2011) The Human African Trypanosomiasis Control and Surveillance Programme of the World Health Organization 2000–2009: The Way Forward. *PLoS Neglected Tropical Diseases* 5: e1007. doi:10.1371/journal.pntd.0001007.
13. De Greef C, Hamers R (1994) The serum resistance-associated (SRA) gene of *Trypanosoma brucei rhodesiense* encodes a variant surface glycoprotein-like protein. *Mol Biochem Parasitol* 68: 277–284.
14. Xong HV, Vanhamme L, Chamekh M, Chimfwembe CE, Van Den Abbeele J, et al. (1998) A VSG expression site-associated gene confers resistance to human serum in *Trypanosoma rhodesiense*. *Cell* 95: 839–846.
15. De Greef C, Imberechts H, Matthyssens G, Van Meirvenne N, Hamers R (1989) A gene expressed only in serum-resistant variants of *Trypanosoma brucei rhodesiense*. *Mol Biochem Parasitol* 36: 169–176. doi:10.1016/0166-6851(89)90189-8.
16. Gibson W (1986) Will the real *Trypanosoma b. gambiense* please stand up. *Parasitol Today* 2: 255–257.
17. Kieft R, Capewell P, Turner CMR, Veitch NJ, Macleod A, et al. (2010) Mechanism of *Trypanosoma brucei gambiense* (group 1) resistance to human trypanosome lytic factor. *Proceedings of the National Academy of Sciences* 107: 16137–16141.
18. DeJesus E, Kieft R, Albright B, Stephens NA, Hajduk SL (2013) A Single Amino Acid Substitution in the *Trypanosoma brucei gambiense* Haptoglobin-Hemoglobin Receptor Abolishes TLF-1 Binding. *PLoS Pathogens* 9: e1003317. doi:10.1371/journal.ppat.1003317.
19. Higgins MK, Tkachenko O, Brown A (2013) Structure of the trypanosome haptoglobin-hemoglobin receptor and implications for nutrient uptake and innate immunity. *Proceedings of the National Academy of Sciences* 110(5):1905–10. doi:10.1073/pnas.1214943110/-/DCSupplemental.
20. Berberof M, Pérez-Morga D, Pays E (2001) A receptor-like flagellar pocket glycoprotein specific to *Trypanosoma brucei gambiense*. *Mol Biochem Parasitol* 113: 127–138.
21. Gibson W, Nemetschke L, Ndong'u J (2010) Conserved sequence of the *TgsGP* gene in Group 1 *Trypanosoma brucei gambiense*. *Infection, Genetics and Evolution* 10: 453–458.
22. Radwanska M, Claes F, Magez S, Magnus E, Pérez-Morga D, et al. (2002) Novel primer sequences for polymerase chain reaction-based detection of *Trypanosoma brucei gambiense*. *Am J Trop Med Hyg* 67: 289–295.
23. Capewell P, Cooper A, Duffy CW, Tait A, Turner CM, et al. (2013) Human and animal trypanosomes in Côte d'Ivoire form a single breeding population. *PLoS ONE*. doi:10.1371/journal.pone.0067852.
24. Symula RE, Beadell JS, Sstrom M (2012) *Trypanosoma brucei gambiense* Group 1 Is Distinguished by a Unique Amino Acid Substitution in the HpHb Receptor Implicated in Human Serum Resistance. *PLoS Neglected Tropical Diseases* 6: e1728.
25. Eisenhaber B, Bork P, Eisenhaber F (1999) Prediction of Potential GPI-modification Sites in Proprotein Sequences. *Journal of Molecular Biology* 292: 741–758. doi:10.1006/jmbi.1999.3069.
26. Böhme U, Cross GAM (2002) Mutational analysis of the variant surface glycoprotein GPI-anchor signal sequence in *Trypanosoma brucei*. *Journal of Cell Science*: 805–816.
27. Balber AE, Frommel TO (1988) *Trypanosoma brucei gambiense* and *T. b. rhodesiense*: Concanavalin A Binding to the Membrane and Flagellar Pocket of Bloodstream and Procyclic Forms. *J Eukaryot Microbiol* 35: 214–219. doi:10.1111/j.1550-7408.1988.tb04326.x.
28. Lecordier L, Vanhollenbecke B, Poelvoorde P, Tebabi P, Paturiaux-Hanocq F, et al. (2009) C-Terminal Mutants of Apolipoprotein L-I Efficiently Kill Both *Trypanosoma brucei brucei* and *Trypanosoma brucei rhodesiense*. *PLoS Pathogens* 5: e1000685. doi:10.1371/journal.ppat.1000685.
29. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, et al. (2010) Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans. *Science* 329: 841–845. doi:10.1126/science.1193032.
30. Frezil JL (1983) Human trypanosomiasis in the Congo. Paris: ORSTOM.
31. Jamongneau V, Ilboudo H, Kaboré J, Kaba D, Koffi M, et al. (2012) Untreated Human Infections by *Trypanosoma brucei gambiense* Are Not 100% Fatal. *PLoS Neglected Tropical Diseases* 6: e1691. doi:10.1371/journal.pntd.0001691.
32. Hirumi H, Hirumi K (1989) Continuous cultivation of *Trypanosoma brucei* blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. *J Parasitol* 75: 985–989.
33. Giroud C, Ottonnes F, Coustou V, Dacheux D, Biteau N, et al. (2009) Murine Models for *Trypanosoma brucei gambiense* Disease Progression—From Silent to Chronic Infections and Early Brain Tropism. *PLoS Neglected Tropical Diseases* 3: e509. doi:10.1371/journal.pntd.0000509.t003.
34. Ligtenberg MJ, Bitter W, Kieft R, Steverding D, Janssens H, et al. (1994) Reconstitution of a surface transferrin binding complex in insect form *Trypanosoma brucei*. *The EMBO Journal* 13: 2565.
35. Bastin P, Bagherzadeh Z, Matthews KR, Gull K (1996) A novel epitope tag system to study protein targeting and organelle biogenesis in *Trypanosoma brucei*. *Mol Biochem Parasitol* 77: 235–239.
36. Capewell P, Veitch NJ, Turner CMR, Raper J, Berriman M, et al. (2011) Differences between *Trypanosoma brucei gambiense* groups 1 and 2 in their resistance to killing by trypanolytic factor 1. *PLoS Neglected Tropical Diseases* 5: e1287.
37. Abramoff MD, Magalhães PJ, Ram SJ (2004) Image processing with ImageJ. *Biophotonics international* 11: 36–42.